2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 57

Genetic Polymorphism of IL-1RN Encoding the IL-1 Receptor Antagonist Predicts Radiographic Severity of Symptomatic Knee OA
Abstract Number: 58

Detecting Novel Candidate Risk Genes in Rheumatoid Arthritis with Gene-Based Association Testing
Abstract Number: 59

Novel Agents for Blocking the Interaction of Immune Complexes with the Activatory FcγRIIIa Receptor
Abstract Number: 60

A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies
Abstract Number: 61

Killer Immunoglobulin-like Receptors Are Associated with Ankylosing Spondylitis
Abstract Number: 62

Increased Frequency of Anti-Drug Antibodies in Patients Carrying Compatible IgG1 Allotypes and Treated with Anti-TNF Antibodies
Abstract Number: 63

Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
Abstract Number: 64

Enrichment of Immune Pathways in Genes Under Geographically Restricted Adaptation in the Gullah African American Population of South Carolina
Abstract Number: 65

Genetic Heterogeneity in the Risk of Lupus Nephritis According to Ancestry
Abstract Number: 66

Very Rare X Chromosome Abnormalities in SLE and SjöGren’s May Localize X Gene Dose Effect
Abstract Number: 67

Polymorphisms of ERAP1, IL23R and TRAILR1 Are Associated with MRI-Sacroiliitis in Early Axial Spondyloarthritis: Data from the French DESIR Cohort
Abstract Number: 68

Epigenetic and Expression Analysis of Ankylosing Spondylitis Association Loci Point to Key Cell Types Driving Disease
Abstract Number: 69

IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis
Abstract Number: 70

Identifying Distal Interactions Between RUNX1 and JIA Associated Single Nucleotide Polymorphisms By Chromosome Conformation Capture
Abstract Number: 71

A Rare Coding Allele in IFIH1 is Protective for Psoriatic Arthritis

« Previous Page
1
…
4
5
6
7
8
…
219
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].